Crown Bioscience, HanX pact shows promise of lymphoma drug
2023-08-24
临床申请临床1期
Preview
来源: FierceBiotech
HX009 has already undergone phase 1 studies in Australia and China for both solid tumor and lymphoma indications.
The partnership between preclinical services firm Crown Bioscience and HanX Biopharmaceutical is showing promise for the Chinese biotech’s investigational drug to treat lymphoma.
A recent preclinical study of HanX’s HX009—which the FDA has greenlit to enter human trials—indicated the bispecific antibody has a strong affinity towards binding to PD-1 but a weaker affinity to CD47. This characteristic allows better targeting to the tumor microenvironment and minimizes potential hematological toxicity, Crown said in an August 22 release.
"These Crown Bioscience studies played an important role in supporting the application of HX009 for the treatment of lymphoma in clinical trials," the CRO said. "They also played an instrumental role in supporting the clearance of HanX’s FDA investigational new drug application, which has paved the way for a U.S.-based phase 1/2 clinical study that will assess HX009 in the treatment of relapsed/refractory lymphoma."
HX009 has already undergone phase 1 studies in Australia and China for solid tumors and lymphoma. Now, HanX has its eye on expanding clinical development into additional indications.
"Crown Bioscience consistently invests in expanding the number and diversity of models for drug development, ensuring that our models accurately represent the relevant clinical disease biology and provide a solid foundation for making informed decisions about novel therapeutics such as HanX's HX009," Ludovic Bourre, Ph.D., Crown's vice president of research and innovation, said in the release.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。